QMQianqian Ming

Qianqian Ming

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qianqian Ming has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular mechanism of Activin receptor inhibition by DLK1

    by Daniel Antfolk, Qianqian Ming, Anna Manturova, Erich J. Goebel, Thomas B. Thompson, Vincent C. Luca

    Delta-like non-canonical Notch ligand 1 (DLK1) influences myogenesis, adipogenesis, and other aspects of human development through a process that is largely attributed to the downregulation of Notch signaling. Here, we show that DLK1 does not bind to Notch receptors or affect ligand-mediated Notch activation, but instead engages the TGF-β superfamily member Activin receptor type 2B (ACVR2B). The crystal structure of the DLK1-ACVR2B complex reveals that DLK1 mimics the binding mode of canonical TGF-β ligands to compete for access to ACVR2B. In functional assays, DLK1 antagonizes Myostatin-ACVR2B signaling to promote myoblast differentiation, rationalizing a mechanism for the role of DLK1 in muscle development and regeneration. Crosstalk between Notch and TGF-β is mediated by interactions between the transcriptional regulators SMAD2/3 and the Notch intracellular domain (NICD), and DLK1 inhibits SMAD2/3-NICD colocalization. These findings indicate that DLK1 acts directly on ACVR2B to inhibit signaling, whereas the observed effects on Notch may be an indirect result of DLK1 interference with NICD-SMAD complex formation.


  • Open Access

    Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

    by Qianqian Ming, Daniel Antfolk, David A. Price, Anna Manturova, Elliot Medina, Srishti Singh, Charlotte Mason, Timothy H. Tran, Keiran S. M. Smalley, Daisy W. Leung, et al.

    The immune checkpoint protein, Lymphocyte activation gene-3 (LAG3), binds Major Histocompatibility Complex Class II (MHC-II) and suppresses T cell activation. Despite the recent FDA approval of a LAG3 inhibitor for the treatment of melanoma, how LAG3 engages MHC-II on the cell surface remains poorly understood. Here, we determine the 3.84 Å-resolution structure of mouse LAG3 bound to the MHC-II molecule I-Ab, revealing that domain 1 (D1) of LAG3 binds a conserved, membrane-proximal region of MHC-II spanning both the α2 and β2 subdomains. LAG3 dimerization restricts the intermolecular spacing of MHC-II molecules, which may attenuate T cell activation by enforcing suboptimal signaling geometry. The LAG3-MHC-II interface overlaps with the MHC-II-binding site of the T cell coreceptor CD4, implicating disruption of CD4-MHC-II interactions as a mechanism for LAG3 immunosuppressive function. Lastly, antibody epitope analysis indicates that multiple LAG3 inhibitors do not recognize the MHC-II-binding interface of LAG3, suggesting a role for functionally distinct mechanisms of LAG3 antagonism in therapeutic development.


  • BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells

    by Kyle K. Payne, Jessica A. Mine, Subir Biswas, Ricardo A. Chaurio, Alfredo Perales-Puchalt, Carmen M. Anadon, Tara Lee Costich, Carly M. Harro, Jennifer Walrath, Qianqian Ming, et al.

    BTN3A1 governs antitumor responses: T lymphocytes are immune cells that can be activated through their gamma delta (γδ) or alpha beta (αβ) receptors. Both T cell types are found in human cancers, but current immunotherapies do not harness their coordinated antitumor activity. Payne et al. found that BTN3A1 and BTN2A1, two members of the butyrophilin family of proteins, partner to activate the most abundant subset of γδ T cells in peripheral blood. Antibodies targeting BTN3A1 redirect γδ T cells to attack cancer cells while also increasing the activity of tumor-specific αβ T cells. Thus, the killing of established tumors by different T cell subsets can be achieved through BTN3A1 targeting and may provide new strategies for cancer immunotherapy. Science , this issue p. 942


  • Chemokine-like factor 1: A promising therapeutic target in human diseases

    by Xiaopeng Cai, Jingwen Deng, Qianqian Ming, Huiqiang Cai, Zhi Chen

    Chemokines are a family of small molecular-weight proteins, being well-known with their important roles in the process of allergic response, immune regulation, cell proliferation, and differentiation. Almost two decades ago, a novel member of this family, chemokine-like factor 1 (CKLF1) was identified. In recent years, it draws much attention of researchers because of its key roles in many types of tissues and its potential implications in a large number of diseases. Up to now, CKLF1 has been shown to have two main functions: broad-spectrum chemotactic activity, and proliferation- and differentiation-promoting abilities. In this review, we would introduce the basic structural features of CKLF1 and its biological functions, and then elaborate the relationships between CKLF1 and human diseases. The cell signaling pathways CKLF1 may be involved in would be discussed and summarized in details. Furthermore, we present the trials of CKLF1-targeted treatments in animal disease models, hoping to provide a few important insights about CKLF1 to both medical researchers and pharmacy, and finally conclude that CKLF1 is a potent, and very promising, therapeutic target. Impact statement: CKLF1, a recently identified chemokine, has been reported by a number of studies to play important roles in quite many diseases. However, the potential pathways that CKLF1 may be involved are not manifested well yet. In our review, we showed the basic molecular structure and major functions of this novel chemokine, and implication in human diseases, such as tumors. To attract more attention, we summarized its signaling pathways and clearly present them in a set of figures. With the overview of the experimental trial of CKLF1-targeting medicines in animal models, we hope to provide a few important insights about CKLF1 to both medical researchers and pharmacy.


  • Molecular engineering strategies for visualizing low-affinity protein complexes

    by Qianqian Ming, David Gonzalez-Perez, Vincent C Luca

    The growing availability of complex structures in the Protein Data Bank has provided key insight into the molecular architecture of protein–protein interfaces. The remarkable diversity observed in protein binding modes is paralleled by a tremendous variation in binding affinities, with interaction half-lives ranging from days to milliseconds. Within the protein interactome, low-affinity binding events have been particularly difficult to visualize by traditional structural methods, which has spurred the development of innovative strategies for reconstituting these short-lived yet biologically essential assemblies. An important takeaway from structural studies of low-affinity systems is that there is no universal solution for stabilizing protein complexes, and approaches such as single-chain fusions, biochemical linkages, and affinity-maturation have each been successful in certain contexts. In this article, we review how advances in molecular engineering have been used to capture weakly associated complexes for structure determination, and we provide perspectives on how the continued application of these methods can shed new light on the “hidden world” of low-affinity interactions.Impact statement: Low-affinity protein interactions, while biologically essential, have been difficult to visualize by traditional methods in structural biology. In this review, we describe a series of innovative molecular engineering strategies that have been used to stabilize weakly bound protein complexes for structure determination. By highlighting several examples from the literature along with potential advantages and disadvantages of the individual approaches, we hope to provide an introductory resource for structural biologists studying low-affinity systems.